IDX719 receives Fast Track designation for Hep C
06:29 EDT 26 Jul 2012 | CentreWatch
Idenix Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company focused on human viral diseases, has been granted Fast Track designation by the FDA for IDX719 for the treatment of chronic hepatitis C infection (HCV).
Original Article: IDX719 receives Fast Track designation for Hep C
More From BioPortfolio on "IDX719 receives Fast Track designation for Hep C"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
